Lifeline Scientific Inc (LSI)
market vs.
industry GROWTH & VALUE
| Trailing 12m | ||||
| PE Ratio (ttm) | 34.6 |
|
|
|
| PEG Ratio (ttm) |
|
|
||
| EPS Growth (ttm) | % |
|
|
|
| Dividend Yield (ttm) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 4.26 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | TTM | 2012E | 2013E | CAGR / Avg | |
| Revenue | $m | ||||||||||
| Operating Profit | $m | ||||||||||
| Net Profit | $m | ||||||||||
| EPS Reported | $ | ||||||||||
| EPS Normalised | $ | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | $ | ||||||||||
| Capex ps | $ | ||||||||||
| Free Cashflow ps | $ | ||||||||||
| Dividends | |||||||||||
| Dividend ps | $ | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | $m | ||||||||||
| Working Capital | $m | ||||||||||
| Net Fixed Assets | $m | ||||||||||
| Net Debt | $m | ||||||||||
| Book Value | $m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | $ | ||||||||||
FINANCIAL BRIEF: For the six months ended 30 June 2012, Lifeline Scientific, Inc revenues increased 21% to $14.3M. Net loss totaled $393K vs. income of $1.5M. Revenues reflect Fee & Sales Revenue increase of 22% to $13.7M. Net loss reflects Change in fair value of warrants decrease from $599K (income) to $0K, Research & Development Expense increase of 50% to $1.5M (expense), Loss on sale of Assets increase from $3K to $48K (expense). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 30th Jun '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: |
Lifeline Scientific, Inc. is a medical technology company engaged in the provision of products and services for cell, tissue and organ transplantation. It sells LifePort Kidney Transporter, related disposables and consumables, and develops future medical devices and related products. The Company operates in two business units: Organ Recovery Systems & Cell and Tissue Systems. Organ Recovery Systems, which develops medical devices, flush and preservation solutions and protocols to improve the process by which donor organs are preserved,from the time of donation to the time of transplantation. Cell and Tissue Systems operates an applied cryobiology and cell therapy research facility focused on improving the long-term storage of living biological materials. It performs scientific research for in vitro diagnostics and allograft cells and tissues, such as heart valves, saphaneous veins and pancreatic islets for transplantation.
Directors: David Kravitz (CEO) ,
No. of Employees: 39 No. of Shareholders: n/a
| Last Annual | December 31st, 2011 |
| Last Interim | June 30th, 2012 |
| Shares in Issue | 26,767,368 |
| Free Float | 26.7m (99.7%) |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | Suite 475W One Pierce Place, ITASCA, 60143, United States |
| Web | http://lifeline-scientific.com/ |
| Phone | +1 847 2940300 |
| Contact | () |
| Registrar | Computershare Investor Service (Channel Islands) Ltd |
| Auditors | Crowe Horwath LLP |
| 7th May | Grant of options |
| 20th Mar | Change of Adviser |
| 28th Feb | Additional Listing |
| 7th Feb | Trading Update |
| 5th Feb | Holding(s) in Company |
| 25th Jan | Additional Listing |
